GALECTIN-3 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA
(Abstract release date: 05/19/16)
EHA Library. Samura B. 06/09/16; 134864; PB1964
Boris Samura
Contributions
Contributions
Abstract
Abstract: PB1964
Type: Publication Only
Background
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progression by displaying intracellular and extracellular activities. Increased expression of galectin-3 (Gal-3) has been associated with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Although modern treatment options for multiple myeloma produce high response rates, the interrelation between elevated Gal-3 and survival rate is not fully understood. Moreover, elevated Gal-3 associates with increased cardiovascular risk. In this context there is possibility to use statins in multiple myeloma patients to prevent unfavorable outcomes under control of Gal-3 level.
Aims
The aim of the study was to investigate an interrelationship between pre-treatment Gal-3 level and one-year survival rate in subjects with multiple myeloma.
Methods
One hundred twelve subjects with multiple myeloma who reached at least partial remission were enrolled in the study. All subjects gave their written informed consent to participation in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=51) and a no statin group (n=61). Among patients in the statin group, 31 patients received 20- mg/day atorvastatin and 20 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3, and NT-pro-brain natriuretic peptide (NT-pro-BNP) were used. Concentrations of Gal-3 and NT-pro-BNP for cumulative survival rate were tested.
Results
Within 1 year progressions were reported in 23 patients (8 statin users (15.7%) and 15 never statin users (24.6%) (P<0.05)). 92 cardiovascular events were reported in 36 patients, (12 statin users (23.5%) and in 24 never statin users (39.3%) (P<0.01)). Lipid lowering effect in statin users was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07–1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03–1.08; P = 0.001), and statin therapy (OR=1.06; 95% CI = 1.01– 1.10; P = 0.001) predicted one-year cumulative cardiovascular events. Gal-3 (odds ratio [OR] = 1.09; 95% CI = 1.05–1.19; P = 0.02), and statin therapy (OR=1.05; 95% CI = 1.01– 1.9; P = 0.04) predicted one-year progression free survival.After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05–1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction model, statin therapy was found as predictor for improving survival in patients with elevated serum Gal-3 level (>14 ng/ml).
Conclusion
Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effects of statins in patients with multiple myeloma.
Session topic: E-poster
Keyword(s): Multiple myeloma, Statin, Survival prediction
Type: Publication Only
Background
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progression by displaying intracellular and extracellular activities. Increased expression of galectin-3 (Gal-3) has been associated with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Although modern treatment options for multiple myeloma produce high response rates, the interrelation between elevated Gal-3 and survival rate is not fully understood. Moreover, elevated Gal-3 associates with increased cardiovascular risk. In this context there is possibility to use statins in multiple myeloma patients to prevent unfavorable outcomes under control of Gal-3 level.
Aims
The aim of the study was to investigate an interrelationship between pre-treatment Gal-3 level and one-year survival rate in subjects with multiple myeloma.
Methods
One hundred twelve subjects with multiple myeloma who reached at least partial remission were enrolled in the study. All subjects gave their written informed consent to participation in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=51) and a no statin group (n=61). Among patients in the statin group, 31 patients received 20- mg/day atorvastatin and 20 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3, and NT-pro-brain natriuretic peptide (NT-pro-BNP) were used. Concentrations of Gal-3 and NT-pro-BNP for cumulative survival rate were tested.
Results
Within 1 year progressions were reported in 23 patients (8 statin users (15.7%) and 15 never statin users (24.6%) (P<0.05)). 92 cardiovascular events were reported in 36 patients, (12 statin users (23.5%) and in 24 never statin users (39.3%) (P<0.01)). Lipid lowering effect in statin users was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07–1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03–1.08; P = 0.001), and statin therapy (OR=1.06; 95% CI = 1.01– 1.10; P = 0.001) predicted one-year cumulative cardiovascular events. Gal-3 (odds ratio [OR] = 1.09; 95% CI = 1.05–1.19; P = 0.02), and statin therapy (OR=1.05; 95% CI = 1.01– 1.9; P = 0.04) predicted one-year progression free survival.After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05–1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction model, statin therapy was found as predictor for improving survival in patients with elevated serum Gal-3 level (>14 ng/ml).
Conclusion
Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effects of statins in patients with multiple myeloma.
Session topic: E-poster
Keyword(s): Multiple myeloma, Statin, Survival prediction
Abstract: PB1964
Type: Publication Only
Background
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progression by displaying intracellular and extracellular activities. Increased expression of galectin-3 (Gal-3) has been associated with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Although modern treatment options for multiple myeloma produce high response rates, the interrelation between elevated Gal-3 and survival rate is not fully understood. Moreover, elevated Gal-3 associates with increased cardiovascular risk. In this context there is possibility to use statins in multiple myeloma patients to prevent unfavorable outcomes under control of Gal-3 level.
Aims
The aim of the study was to investigate an interrelationship between pre-treatment Gal-3 level and one-year survival rate in subjects with multiple myeloma.
Methods
One hundred twelve subjects with multiple myeloma who reached at least partial remission were enrolled in the study. All subjects gave their written informed consent to participation in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=51) and a no statin group (n=61). Among patients in the statin group, 31 patients received 20- mg/day atorvastatin and 20 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3, and NT-pro-brain natriuretic peptide (NT-pro-BNP) were used. Concentrations of Gal-3 and NT-pro-BNP for cumulative survival rate were tested.
Results
Within 1 year progressions were reported in 23 patients (8 statin users (15.7%) and 15 never statin users (24.6%) (P<0.05)). 92 cardiovascular events were reported in 36 patients, (12 statin users (23.5%) and in 24 never statin users (39.3%) (P<0.01)). Lipid lowering effect in statin users was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07–1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03–1.08; P = 0.001), and statin therapy (OR=1.06; 95% CI = 1.01– 1.10; P = 0.001) predicted one-year cumulative cardiovascular events. Gal-3 (odds ratio [OR] = 1.09; 95% CI = 1.05–1.19; P = 0.02), and statin therapy (OR=1.05; 95% CI = 1.01– 1.9; P = 0.04) predicted one-year progression free survival.After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05–1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction model, statin therapy was found as predictor for improving survival in patients with elevated serum Gal-3 level (>14 ng/ml).
Conclusion
Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effects of statins in patients with multiple myeloma.
Session topic: E-poster
Keyword(s): Multiple myeloma, Statin, Survival prediction
Type: Publication Only
Background
Galectins are a family of lectin molecules that have emerged as key players in inflammation and tumor progression by displaying intracellular and extracellular activities. Increased expression of galectin-3 (Gal-3) has been associated with chronic myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Although modern treatment options for multiple myeloma produce high response rates, the interrelation between elevated Gal-3 and survival rate is not fully understood. Moreover, elevated Gal-3 associates with increased cardiovascular risk. In this context there is possibility to use statins in multiple myeloma patients to prevent unfavorable outcomes under control of Gal-3 level.
Aims
The aim of the study was to investigate an interrelationship between pre-treatment Gal-3 level and one-year survival rate in subjects with multiple myeloma.
Methods
One hundred twelve subjects with multiple myeloma who reached at least partial remission were enrolled in the study. All subjects gave their written informed consent to participation in the study. Patients were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=51) and a no statin group (n=61). Among patients in the statin group, 31 patients received 20- mg/day atorvastatin and 20 patients received 40-mg/day atorvastatin. None of the patients had received any lipid-modulating medications, including statins or fibrates, before enrollment. Observation period was up to 1 year. Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of Gal-3, and NT-pro-brain natriuretic peptide (NT-pro-BNP) were used. Concentrations of Gal-3 and NT-pro-BNP for cumulative survival rate were tested.
Results
Within 1 year progressions were reported in 23 patients (8 statin users (15.7%) and 15 never statin users (24.6%) (P<0.05)). 92 cardiovascular events were reported in 36 patients, (12 statin users (23.5%) and in 24 never statin users (39.3%) (P<0.01)). Lipid lowering effect in statin users was associates with declined serum Gal-3 level, whereas in not statin users similar response was not appeared. No any changes in hemodynamics and other biomarkers between both cohorts were found. Univariate logistic regression had exhibited that Gal-3 (odds ratio [OR] = 1.13; 95% CI = 1.07–1.25; P = 0.003), NT-proBNP (OR=1.05; 95% CI = 1.03–1.08; P = 0.001), and statin therapy (OR=1.06; 95% CI = 1.01– 1.10; P = 0.001) predicted one-year cumulative cardiovascular events. Gal-3 (odds ratio [OR] = 1.09; 95% CI = 1.05–1.19; P = 0.02), and statin therapy (OR=1.05; 95% CI = 1.01– 1.9; P = 0.04) predicted one-year progression free survival.After adjustment on statin therapy, Gal-3 remained independent predictor one-year cumulative cardiovascular events (OR = 1.07; 95% CI = 1.05–1.10; p = 0.001). When initial serum Gal-3 level has incorporated into prediction model, statin therapy was found as predictor for improving survival in patients with elevated serum Gal-3 level (>14 ng/ml).
Conclusion
Elevated pre-treatment galectin-3 level was found a powerful predictor of positive effects of statins in patients with multiple myeloma.
Session topic: E-poster
Keyword(s): Multiple myeloma, Statin, Survival prediction
{{ help_message }}
{{filter}}